MedTrace Logo

Efficacy of α-blocker or 5-ARI Withdrawal to Continued Combination Therapy on the Maintenance of LUTS in Men With BPH

NCT05023824 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2021-08-27

No results posted yet for this study

Summary

The investigators compare the efficacy of alpha-blocker and 5-ARI withdrawal to continued combination therapy on the maintenance of LUTS and improvement of quality of life outcomes in men with benign prostatic hyperplasia.

Conditions

  • Prostatic Hyperplasia
  • Prostate Hyperplasia
  • Prostatic Hypertrophy

Interventions

DRUG

alpha-blocker or 5-ARI withdrawal

Withdrawal of either alpha-blocker or 5-ARI

DRUG

Maintenance of alpha-blocker and 5-ARI

Maintenance of alpha-blocker and 5-ARI

Sponsors & Collaborators

  • Gangnam Severance Hospital

    lead OTHER

Principal Investigators

  • Kyo Chul Koo, MD, PhD · Yonsei University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-08
Primary Completion
2023-12-07
Completion
2023-12-07
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05023824 on ClinicalTrials.gov